The “first-generation’ EGFR inhibitors, i.e., gefitinib and erlotinib, are reversible, ATP-competitive inhibitors that target exon 19 deletion and L858R mutant EGFR selectively and have been used in the treatment of EGFR-mutant NSCLC and pancreatic cancer, achieving up to a 72% response rate (RR) and nearly 10 months PFS [17–19]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.